Levee Medical, Inc.

Levee Medical is thrilled to announce the appointment of Michael Henson to its Board of Directors. Mr. Henson brings over 30 years of leadership experience, having founded or served as CEO and Chairman/Board Member for more than 20 successful healthcare firms, including guiding six to IPOs and 12 to acquisition by large multinational healthcare companies. His extensive background in medical devices and biotechnology will be invaluable as Levee Medical continues to drive forward its groundbreaking innovation for post-prostatectomy patients. “Mike’s track record speaks for itself,” says Bruce Choi, Founder and Chairman of Levee Medical. “His leadership and experience in growing companies and bringing them to market is exactly what we need as we scale.”    Mr. Henson has an impressive history of guiding emerging companies through growth phases, including seeing many acquired by large multinational firms. His most recent success, the sale of Rebound Therapeutics to Integra LifeSciences, further solidifies his reputation for creating value and driving successful outcomes. "I am excited to join Levee Medical at such a pivotal time in its growth,” says Mr. Henson. “The company is at the forefront of developing cutting-edge urologic therapies, and I look forward to supporting their mission to improve patient outcomes worldwide.”    With this appointment, Levee Medical strengthens its commitment to innovation and leadership in improving recovery outcomes for prostate cancer patients undergoing surgery. Mr. Henson's addition to the Board will play a key role in shaping the company's future as it grows and delivers life-changing solutions for patients. 

September is Prostate Cancer Awareness Month, a time to reflect on the 1 in 8 men in the U.S. who will be diagnosed with prostate cancer in their lifetime. Each year, over 90,000 men undergo radical prostatectomies, facing challenges in recovery. We at Levee Medical are dedicated to advancing post-prostatectomy recovery so patients can return to the activities they love. Because life after prostatectomy deserves to be brilliant. #prostatecancerawareness #lifeafterprostatectomy

We're thrilled to announce the publication of the Initial Experience with an Absorbable Urologic Scaffold, featured in the prestigious Urologia Internationalis. This article highlights an innovative approach that aims to mitigate urinary incontinence following radical prostatectomy, offering patients new hope. In addition, we're pleased to share that enrollment for our ARID OUS early feasibility study is now complete. As we eagerly await short- and long-term data, the initial results are highly encouraging and reinforce the potential impact of our technology. Stay tuned for more updates as we continue to advance our mission of redefining the journey of prostatectomy recovery. #menshealth #urologicinnovation #patientoutcomes

We had an incredible experience at SRS 2024 in Orlando! We are thrilled that Dr. Michael Ferrandino delivered the first international presentation on our innovative Voro Urologic Scaffold, marking a significant milestone for our team. Additionally, we have successfully enrolled 25 patients in the ARID OUS feasibility study. Thank you to everyone who visited us and contributed to making this event a success. Together, we’re advancing urologic care! #SRS2024 #innovationinurology #prostatecancer

Join us tomorrow at SRS 2024 for Dr. Michael Ferrandino's presentation, "Initial Experience with an Absorbable Urologic Scaffold to Mitigate Early Urinary Incontinence Following Radical Prostatectomy: A Report of Two Cases." Don't miss it at 9:30 AM in the Wisteria Room. #SRS2024 #urology #medicalinnovation

SRS 2024 is well underway! Please join us at the abstract session on Saturday morning, June 22nd, with Dr. Ferrandino.

Join us at SRS 2024 and attend Dr. Michael Ferrandino's presentation, "Initial Experience with an Absorbable Urologic Scaffold to Mitigate Early Urinary Incontinence Following Radical Prostatectomy: A Report of Two Cases" on Saturday, June 22, 2024, at 9:30 AM in the Wisteria Room. #SRS2024 #urology #medicalinnovation

Exciting news! We are happy to announce we have secured funding commitments to accelerate the development of the Voro Urologic Scaffold, aimed at improving recovery outcomes post-prostatectomy. Additionally, we have achieved multiple enrollment milestones in our ALTO and ARID studies, showing promising preliminary results. These achievements energize us and we remain dedicated to our mission of enhancing the lives of men post-prostatectomy. #medicalinnovation #urology #prostatecancer Read more in our press release:

We look forward to seeing you at the annual SRS 2024 meeting in Orlando, June 20th to 23rd. To learn about the Voro® Urologic Scaffold visit us at Booth #C116. Interested in clinical research opportunities? Contact Karen Cornett, RN, MSN at kcornett@leveemedical.com to schedule a time slot. See you there! #SRS2024 #urology #medicalinnovation

We look forward to seeing you at the annual SRS 2024 meeting in Orlando, June 20th to 23rd. To learn about the Voro® Urologic Scaffold visit us at Booth #C116. Interested in clinical research opportunities? Contact Karen Cornett, RN, MSN at kcornett@leveemedical.com to schedule a time slot. See you there! #SRS2024 #urology #medicalinnovation